# Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

> **NCT07130786** · PHASE2 · RECRUITING · sponsor: **Ayal A. Aizer, MD** · enrollment: 150 (estimated)

## Conditions studied

- Seizures
- Primary Motor Cortex
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Brain Metastases, Adult
- Brain Metastases From Extra-cranial Solid Tumors

## Interventions

- **DRUG:** Levetiracetam (Keppra)

## Key facts

- **NCT ID:** NCT07130786
- **Lead sponsor:** Ayal A. Aizer, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-23
- **Primary completion:** 2029-02
- **Final completion:** 2030-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130786, "Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07130786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*